The Indian pharma industry, which is knocked repeatedly for poor manufacturing practices across the planet, seems to have pulled its strings relatively. American drug firms got 54 warning letters by the USFDA, while India on its heels with 17 such notices within the year ended September (US financial year). China tailing with 14 warnings.

A company smacked with a warning letter is stopped from introducing new products within the US, restricting its ability to extend sales within the world’s top pharmaceutical market. Earlier, reportedly emerging economies like India or China topped the list.
Data integrity issues that include inappropriate manufacturing practices and lascivious in testing medicines, still corrode the industry with 32 of 98 warning letters in 2019. within the previous year, 34 of 94 warning letters were thanks to data integrity lapses, which have a big impact on drug product quality.
Several pharma companies were hauled up by the US regulator over issues like careless documentation, neglecting test results and unhygienic manufacturing facilities with open toilet drains. Indian companies command almost 35% share within the highly lucrative US generic market, valued at closely $70 billion.
In 2019, major companies including Lupin, Aurobindo, Glenmark and Emcure Pharma were issued warning letters for significant violations of current good manufacturing practise regulations. Typically, the action follows inspections by the US regulator.US